Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate
- PMID: 8187079
Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate
Abstract
Phenylacetate is a naturally occurring plasma component that suppresses the growth of tumor cells and induces differentiation in vitro. To evaluate the in vivo potential and preventive and therapeutic antitumor efficacy of sodium phenylacetate against malignant brain tumors, Fischer 344 rats (n = 50) bearing cerebral 9L gliosarcomas received phenylacetate by continuous s.c. release starting on the day of tumor inoculation (n = 10) using s.c. osmotic minipumps (550 mg/kg/day for 28 days). Rats with established brain tumors (n = 12) received continuous s.c. phenylacetate supplemented with additional daily i.p. dose (300 mg/kg). Control rats (n = 25) were treated in a similar way with saline. Rats were sacrificed during treatment for electron microscopic studies of their tumors, in vivo proliferation assays, and measurement of phenylacetate levels in the serum and cerebrospinal fluid. Treatment with phenylacetate extended survival when started on the day of tumor inoculation (P < 0.01) or 7 days after inoculation (P < 0.03) without any associated adverse effects. In the latter group, phenylacetate levels in pooled serum and cerebrospinal fluid samples after 7 days of treatment were in the therapeutic range as determined in vitro (2.45 mM in serum and 3.1 mM in cerebrospinal fluid). Electron microscopy of treated tumors demonstrated marked hypertrophy and organization of the rough endoplasmic reticulum, indicating cell differentiation, in contrast to the scant and randomly distributed endoplasmic reticulum in tumors from untreated animals. In addition, in vitro studies demonstrated dose-dependent inhibition of the rate of tumor proliferation and restoration of anchorage dependency, a marker of phenotypic reversion. Phenylacetate, used at clinically achievable concentrations, prolongs survival of rats with malignant brain tumors through induction of tumor differentiation. Its role in the treatment of brain tumors and other cancers should be explored further.
Similar articles
-
[Therapeutic efficacy of intracarotid infusion of 20% mannitol with ACNU in Fischer rats with intracerebrally implanted 9L gliosarcoma].Gan To Kagaku Ryoho. 1989 May;16(5):2059-65. Gan To Kagaku Ryoho. 1989. PMID: 2499268 Japanese.
-
Sustained release of low-dose ganciclovir from a silicone formulation prolonged the survival of rats with gliosarcomas under herpes simplex virus thymidine kinase suicide gene therapy.Gene Ther. 2002 Dec;9(24):1653-8. doi: 10.1038/sj.gt.3301860. Gene Ther. 2002. PMID: 12457278
-
A thermal gel depot for local delivery of paclitaxel to treat experimental brain tumors in rats.J Neurosurg. 2010 Aug;113(2):210-7. doi: 10.3171/2009.11.JNS08162. J Neurosurg. 2010. PMID: 20001591
-
Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.Cancer Res. 2001 Dec 15;61(24):8769-74. Cancer Res. 2001. PMID: 11751397
-
Butyrate and phenylacetate as differentiating agents: practical problems and opportunities.J Cell Biochem Suppl. 1995;22:247-53. doi: 10.1002/jcb.240590831. J Cell Biochem Suppl. 1995. PMID: 8538206 Review.
Cited by
-
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors.Invest New Drugs. 2007 Apr;25(2):131-8. doi: 10.1007/s10637-006-9017-4. Epub 2006 Oct 20. Invest New Drugs. 2007. PMID: 17053987 Clinical Trial.
-
Potential of antineoplastons in diseases of old age.Drugs Aging. 1995 Sep;7(3):157-67. doi: 10.2165/00002512-199507030-00001. Drugs Aging. 1995. PMID: 8535046 Review. No abstract available.
-
Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate.J Neurooncol. 2002 Sep;59(3):239-42. doi: 10.1023/a:1019905127442. J Neurooncol. 2002. PMID: 12241121
-
New approach to tumor therapy for inoperable areas of the brain: chronic intraparenchymal drug delivery.J Neurooncol. 2002 Nov;60(2):151-8. doi: 10.1023/a:1020626419269. J Neurooncol. 2002. PMID: 12635662
-
Inhibitory effects of phenylbutyrate on the proliferation, morphology, migration and invasiveness of malignant glioma cells.J Neurooncol. 1998 Apr;37(2):97-108. doi: 10.1023/a:1005865125588. J Neurooncol. 1998. PMID: 9524087
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical